Business / Finance

RSS

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.

3 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Epocrates prices initial public offering at $16.00 per share

Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.

3 Feb 2011

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $15.50 per share.

3 Feb 2011

Scil Proteins concludes financing round with BioNet Holding for €24 million

Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two products derived from the Company's Affilin platform into clinical Phase I over the next three years.

2 Feb 2011

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group).

2 Feb 2011

Thermo Fisher Scientific 2010 revenues increase 7% to $10.79 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2010.

From Thermo Fisher Scientific Inc. 2 Feb 2011

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net sales and earnings per share (EPS) guidance for the full year and first quarter 2011.

2 Feb 2011

Boston-based Research 2.0 begins Viral Genetics coverage, publishes initial report

Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.

2 Feb 2011

Intrexon announces AgBio Division launch and Agarigen acquisition

Intrexon Corporation, a next generation synthetic biology company, today announced the launch of its Agricultural Biotechnology (AgBio) Division in Research Triangle Park, North Carolina and the acquisition of Agarigen, Inc., a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.

2 Feb 2011

Pfizer board authorizes new $5 billion share repurchase program

Pfizer Inc. today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company's total repurchase authorization to $9 billion.

2 Feb 2011

Seattle Genetics to sell common stock in underwritten public offering

Seattle Genetics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Seattle Genetics.

1 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of Notes, solely to cover over-allotments.

1 Feb 2011